WA-KYMETA
23.3.2022 14:02:14 CET | Business Wire | Press release
Kymeta (www.kymetacorp.com ), the communications company making mobile global, and IP Access International (www.ipinternational.net ), a leading mobile and fixed satellite solutions provider, announced today the signing of a partnership agreement to co-develop and distribute optimized solutions using Kymeta terminals, broadband and LTE services to first responders across North America.
Today, IP Access operates the nation’s largest public safety satellite network, which includes over 1,000 agency customers encompassing 1,700 unique endpoints. This agreement to deliver optimized solutions will combine Kymeta’s resilient and cost-effective electronically-steered flat panel technology with IP Access’ experience building public safety networks for mobility and remote connectivity where it has not previously existed. It will utilize coverage and bandwidth on a jointly developed, multi layered broadband network optimized specifically for public safety customers. The Kymeta enabled solution allows communication and interoperability among devices, further extending the reach of the IP Access RedPHONE service even if there is an internet outage due to malware or denial-of-service attacks.
“Kymeta is dedicated to bringing access to always-on, reliable, and mission-critical communications while on the move to the public safety and first responder market,” said Bill Marks, EVP and Chief Development Officer of Kymeta. “Our u8 products have been deployed around the world and provide a real-world solution for the defense, government, public safety, and commercial industries by enabling connectivity that is ubiquitous and more robust than ever before. We are pleased to partner with a well-established leader like IP Access who has earned the continued trust and loyalty of first responders for over two decades through the delivery of consistent, reliable products and services.”
“IP Access looks forward to a strong partner relationship with Kymeta in our joint efforts to provide resilient communications to response teams who protect and save lives,” said Bryan Hill, CEO of IP Access International. “Our customers are indifferent to what network they are on so long as it is reliable. Our goal at IP Access is to provide them with the connectivity they need on every possible network. That means 4G, 5G, GEO, MEO and LEO. Customers have capital constraints, and it is our responsibility to deliver solutions that are future proof and that is why we are partnering with Kymeta.”
The Kymeta u8 product family for mobile broadband communications are low-maintenance and low-profile for resilient communications-on-the-move (COTM) and communications-on-the-pause (COTP). The u8 product family also offers a pathway to low Earth orbit (LEO) networks as they come online over the next several years. The new partnership will allow IP Access to provide solutions that perform on today’s satellites and are enabled to work on future LEO satellite networks.
The partnership illustrates the commitment from both companies to enable critical mobile connectivity solutions for public safety and for disaster response that are more robust than ever before. Kymeta and IP Access have committed to a significant volume of equipment and satellite bandwidth to quickly fulfill the needs of public safety and first responders and grow the product suite and coverage in support of this important market.
About Kymeta
Kymeta is the leader in unlocking the potential of broadband satellite connectivity, combined with cellular networks, to satisfy the overwhelming demand for communications-on-the-move and making mobile global. Kymeta satellite connectivity solutions offer unique, complete, and turnkey bundled solutions to the market based on best-in-class technologies and tailored customer-centric services that meet and exceed customer mission requirements. These solutions, in tandem with the company’s flat-panel satellite antenna, the first of its kind, and Kymeta services provide revolutionary mobile connectivity on satellite and hybrid satellite-cellular networks to customers around the world. Backed by U.S. and international patents and licenses, the Kymeta terminal addresses the need for low-power, low-cost, and high-throughput communication systems that have no moving parts. Kymeta makes connecting easy – for any vehicle, vessel, aircraft, or fixed platform.
Kymeta is a privately held company based in Redmond, Washington.
For more information, visit kymetacorp.com
About IP Access International
IP Access is a leading provider of mobile and fixed satellite internet solutions with over 20 years experience serving the satellite industry as a domestic and global provider. IP Access provides complete satellite communications solutions inclusive of satellite network offerings, terminal hardware, and installation and support services. Incorporated in 1999, today IP Access operates the nation’s largest satellite network of public safety agencies, which includes over 1000 agency customers encompassing 1,700 unique endpoints. At the heart of the IP Access offering is the SELECT Network, providing multiple satellite options and multiple teleports, ensuring protection against regional disasters and infrastructure disruptions while also allowing for on-demand user selectable satellite service in the event of line-of-sight or look angle obstructions.
For more information, visit ipinternational.net
View source version on businesswire.com: https://www.businesswire.com/news/home/20220323005277/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
